Mersana Therapeutics (MRSN) Earning Somewhat Critical Media Coverage, Analysis Shows

News coverage about Mersana Therapeutics (NASDAQ:MRSN) has been trending somewhat negative this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mersana Therapeutics earned a media sentiment score of -0.02 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.4011266089072 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

MRSN opened at $14.97 on Friday. The firm has a market cap of $342.00 and a PE ratio of -4.65. Mersana Therapeutics has a fifty-two week low of $12.45 and a fifty-two week high of $21.01.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings data on Wednesday, March 28th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.13). The firm had revenue of $3.26 million during the quarter, compared to analyst estimates of $4.22 million. research analysts anticipate that Mersana Therapeutics will post -2.53 earnings per share for the current year.

MRSN has been the subject of a number of research reports. HC Wainwright set a $33.00 price target on Mersana Therapeutics and gave the company a “buy” rating in a research note on Friday, March 2nd. Zacks Investment Research raised Mersana Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, January 11th. JPMorgan Chase lowered Mersana Therapeutics from an “overweight” rating to a “neutral” rating and set a $23.00 price target for the company. in a research note on Monday, March 19th. ValuEngine raised Mersana Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Leerink Swann reaffirmed an “outperform” rating on shares of Mersana Therapeutics in a research note on Wednesday, March 28th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Mersana Therapeutics presently has an average rating of “Hold” and a consensus target price of $24.80.

ILLEGAL ACTIVITY NOTICE: “Mersana Therapeutics (MRSN) Earning Somewhat Critical Media Coverage, Analysis Shows” was originally published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3341053/mersana-therapeutics-mrsn-earning-somewhat-critical-media-coverage-analysis-shows.html.

About Mersana Therapeutics

Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.

Insider Buying and Selling by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Head to Head Review: On Assignment  & Its Competitors
Head to Head Review: On Assignment & Its Competitors
Contrasting Mountain Province Diamonds  and Its Rivals
Contrasting Mountain Province Diamonds and Its Rivals
Matador Resources  versus Callitas Health  Head-To-Head Comparison
Matador Resources versus Callitas Health Head-To-Head Comparison
Cousins Properties  Earns Market Perform Rating from Analysts at Wells Fargo
Cousins Properties Earns Market Perform Rating from Analysts at Wells Fargo
$63.31 Million in Sales Expected for First Bancorp  This Quarter
$63.31 Million in Sales Expected for First Bancorp This Quarter
Royal Bank of Canada Reaffirms “Hold” Rating for BancorpSouth Bank
Royal Bank of Canada Reaffirms “Hold” Rating for BancorpSouth Bank


© 2006-2018 Ticker Report. Google+.